These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24730443)

  • 1. Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.
    Waschbisch A; Sammet L; Schröder S; Lee DH; Barrantes-Freer A; Stadelmann C; Linker RA
    Clin Exp Immunol; 2014 Aug; 177(2):404-11. PubMed ID: 24730443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
    Harrer A; Pilz G; Wipfler P; Oppermann K; Sellner J; Hitzl W; Haschke-Becher E; Afazel S; Rispens T; van der Kleij D; Trinka E; Kraus J
    Clin Exp Immunol; 2015 Jun; 180(3):383-92. PubMed ID: 25603898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of viral and self-antigens by T
    Paroni M; Maltese V; De Simone M; Ranzani V; Larghi P; Fenoglio C; Pietroboni AM; De Riz MA; Crosti MC; Maglie S; Moro M; Caprioli F; Rossi R; Rossetti G; Galimberti D; Pagani M; Scarpini E; Abrignani S; Geginat J
    J Allergy Clin Immunol; 2017 Sep; 140(3):797-808. PubMed ID: 28237728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
    Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
    PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.
    Mancuso R; Saresella M; Hernis A; Marventano I; Ricci C; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2012 Dec; 10():248. PubMed ID: 23232085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.
    Nielsen BR; Ratzer R; Börnsen L; von Essen MR; Christensen JR; Sellebjerg F
    J Neuroimmunol; 2017 Sep; 310():17-25. PubMed ID: 28778440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
    Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
    PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
    de Andrés C; Teijeiro R; Alonso B; Sánchez-Madrid F; Martínez ML; Guzmán de Villoria J; Fernández-Cruz E; Sánchez-Ramón S
    PLoS One; 2012; 7(4):e34103. PubMed ID: 22496780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
    Chalkias S; Dang X; Bord E; Stein MC; Kinkel RP; Sloane JA; Donnelly M; Ionete C; Houtchens MK; Buckle GJ; Batson S; Koralnik IJ
    Ann Neurol; 2014 Jun; 75(6):925-34. PubMed ID: 24687904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.
    Jilek S; Mathias A; Canales M; Lysandropoulos A; Pantaleo G; Schluep M; Du Pasquier RA
    Mult Scler; 2014 Jun; 20(7):837-42. PubMed ID: 24258149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis.
    Varghese JF; Kaskow BJ; von Glehn F; Case J; Li Z; Julé AM; Berdan E; Ho Sui SJ; Hu Y; Krishnan R; Chitnis T; Kuchroo VK; Weiner HL; Baecher-Allan CM
    Front Immunol; 2024; 15():1360219. PubMed ID: 38745667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy.
    Hendel-Chavez H; de Goër de Herve MG; Giannesini C; Mazet AA; Papeix C; Louapre C; Chardain A; Boutarfa N; Théaudin M; Adams D; Gasnault J; Stankoff B; Taoufik Y
    J Virol; 2013 May; 87(10):6055-9. PubMed ID: 23514886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A complex role of herpes viruses in the disease process of multiple sclerosis.
    Wuest SC; Mexhitaj I; Chai NR; Romm E; Scheffel J; Xu B; Lane K; Wu T; Bielekova B
    PLoS One; 2014; 9(8):e105434. PubMed ID: 25148387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.